NTLA
Intellia Therapeutics, Inc.
$12.11
-1.94%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusBuy (54%)
Inst. Holders50 funds
Inst. Value$1.1B
Inst. Activity19 buys / 8 sells
Insider Activity0B / 2S
Insider Net $-$25.1K
Reddit Sentiment50° Neutral
SEC Reports6
Press Releases4
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0001652130·Prev Close $12.35
Recent Activity
Jun 12, 2026
short_volume
Short Volume: NTLA — 60.8% short (1.5M / 2.5M)
Short: 1,494,364 | Exempt: 10,902 | TRF Vol: 2,457,514 | Short Ratio: 60.8% | Off-exchange volume (d
Jun 9, 2026
Insider
Verwiel Frank was granted 13,300 shares
Director
Jun 9, 2026
Insider
GOODMAN JESSE was granted 9,200 shares
Director
Jun 9, 2026
Insider
GOODMAN JESSE was granted 13,300 shares
Director
Jun 1, 2026
SEC
Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p
PRESS-RELEASE — Impact 5/10
May 11, 2026
SEC
Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3M loss in Q1 2025, w
8-K — Impact 6/10
Apr 27, 2026
SEC
Intellia Therapeutics announced positive Phase 3 topline data for its investigational CRISPR-based therapy lonvo-z in he
8-K — Impact 8/10
Inst.
JUPITER ASSET MANAGEMENT LTD — ADD
1,781,063 shares ($22.8M)
Price Targets
$26.63
+119.9% upside
Strong Buy
Current $12.11
Low $8.00
Median $19.00
High $95.00
19 analysts
$8.00
$95.00
Analyst Ratings
5Strong Buy
10Buy
11Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform → Market Perform |
| May 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 12, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 12, 2026 | Wedbush | REITERATE | Neutral → Neutral |
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.80 ▲ +9.7% | $-0.95 — $-0.63 | 19% YoY | 17 |
| Next Q | $-0.79 ▲ +11.3% | $-0.96 — $-0.64 | 14% YoY | 17 |
| Current FY | $-3.17 ▲ +4.3% | $-3.75 — $-2.76 | 17% YoY | 19 |
| Next FY | $-1.80 ▲ +4.7% | $-4.00 — $12.95 | 43% YoY | 19 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p
Jun 1, 2026
MIXED
8-K
6/10
Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3M loss in Q1 2025, w
May 11, 2026
BEARISH
Press
6/10
Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, with an underwriter opt
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ARK Investment Management LLC | $186.0M | — |
| BlackRock, Inc. | $155.8M | — |
| STATE STREET CORP | $88.7M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $79.8M | — |
| D. E. Shaw & | $73.4M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Verwiel Frank | A | $0.00 |
| Jun 9, 2026 | GOODMAN JESSE | A | $0.00 |
| Jun 9, 2026 | GOODMAN JESSE | A | $0.00 |
| Jun 9, 2026 | Verwiel Frank | A | $0.00 |
| Jun 9, 2026 | Keresty Georgia | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.1B total value (85,697,845 shares) as of 2026-Q1. Top holders: ARK, BlackRock,, STATE. Net buying activity: 19 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 14,509,247 | $186.0M | 16.9% | — |
| 2 | BlackRock, Inc. | 12,155,806 | $155.8M | 14.2% | — |
| 3 | STATE STREET CORP | 6,922,676 | $88.7M | 8.1% | ADD +29.1% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,223,325 | $79.8M | 7.3% | — |
| 5 | D. E. Shaw & Co., Inc. | 5,728,177 | $73.4M | 6.7% | DOUBLED +139.2% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,084,105 | $65.2M | 5.9% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 4,705,901 | $60.3M | 5.5% | — |
| 8 | DIMENSIONAL FUND ADVISORS LP | 2,318,110 | $29.7M | 2.7% | — |
| 9 | MORGAN STANLEY | 2,081,397 | $26.7M | 2.4% | TRIM -61.3% |
| 10 | FMR LLC | 2,067,222 | $26.5M | 2.4% | — |
| 11 | Sumitomo Mitsui Trust Group, Inc. | 1,973,061 | $25.3M | 2.3% | — |
| 12 | JUPITER ASSET MANAGEMENT LTD | 1,781,063 | $22.8M | 2.1% | ADD +71.6% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,667,800 | $21.4M | 1.9% | — |
| 14 | GOLDMAN SACHS GROUP INC | 1,628,241 | $20.9M | 1.9% | — |
| 15 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1,611,534 | $20.7M | 1.9% | — |
| 16 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,397,243 | $17.9M | 1.6% | NEW |
| 17 | BANK OF AMERICA CORP /DE/ | 1,381,703 | $17.7M | 1.6% | DOUBLED +105.2% |
| 18 | STIFEL FINANCIAL CORP | 1,012,706 | $13.0M | 1.2% | — |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 941,285 | $12.1M | 1.1% | — |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 748,636 | $9.6M | 0.9% | DOUBLED +188.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JUPITER ASSET MANAGEMENT LTD | ADD | 1,037,918 | 1,781,063 | +71.6% | $22.8M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 1,397,243 | — | $17.9M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 259,709 | 748,636 | +188.3% | $9.6M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | 193,026 | 730,122 | +278.3% | $9.4M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 98,597 | 186,781 | +89.4% | $2.4M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 73,526 | 128,209 | +74.4% | $1.6M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 74,028 | 109,290 | +47.6% | $1.4M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | TRIM | 189,076 | 89,223 | -52.8% | $1.1M | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 15,202 | 73,923 | +386.3% | $947.7K | 2026-Q1 |
| Hudson Bay Capital Management LP | NEAR_EXIT | 315,000 | 60,000 | -81.0% | $769.2K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 9,599 | 59,432 | +519.1% | $761.9K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 18,118 | 45,111 | +149.0% | $578.3K | 2026-Q1 |
| CWM, LLC | ADD | 22,890 | 44,939 | +96.3% | $576.1K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 17,653 | 22,465 | +27.3% | $288.0K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 10,345 | 18,808 | +81.8% | $246.9K | 2026-Q1 |
| Pictet Asset Management Holding SA | ADD | 11,504 | 16,933 | +47.2% | $217.1K | 2026-Q1 |
| Atria Investments, Inc | ADD | 10,392 | 13,076 | +25.8% | $167.6K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | NEAR_EXIT | 40,400 | 10,100 | -75.0% | $129.5K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 31,735 | 6,098 | -80.8% | $78.2K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 1,734 | 3,592 | +107.2% | $46.0K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 2,604 | 3,552 | +36.4% | $45.5K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,422 | 1,973 | +38.7% | $25.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 1,452 | 617 | -57.5% | $7.9K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 764,890 | 502,337 | -34.3% | $6.4K | 2026-Q1 |
| TD Waterhouse Canada Inc. | ADD | 200 | 281 | +40.5% | $3.7K | 2026-Q1 |
14 unique insiders with 29 transactions. Net insider value: -$25.1K ($0.00 bought, $25.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Verwiel Frank | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | GOODMAN JESSE | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | GOODMAN JESSE | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | Verwiel Frank | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Keresty Georgia | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Bhanji Muna | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Bhanji Muna | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | CHASE WILLIAM J | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Cohen Fred E | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | CHASE WILLIAM J | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | Cohen Fred E | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Goff Brian | Director | AWARD | 9,200 | — | — |
| Jun 9, 2026 | Goff Brian | Director | AWARD | 13,300 | — | — |
| Jun 9, 2026 | Keresty Georgia | Director | AWARD | 13,300 | — | — |
| Mar 2, 2026 | Clark Eliana | EVP, Chief Technical Officer | SELL | 607 | $13.78 | $8.4K |
| Mar 2, 2026 | BASTA JAMES | EVP, General Counsel | SELL | 1,211 | $13.78 | $16.7K |
| Mar 1, 2026 | Lebwohl David | EVP, Chief Medical Officer | AWARD | 9,943 | — | — |
| Mar 1, 2026 | Clark Eliana | EVP, Chief Technical Officer | AWARD | 7,353 | — | — |
| Mar 1, 2026 | Clark Eliana | EVP, Chief Technical Officer | AWARD | 10,505 | — | — |
| Mar 1, 2026 | Dube Michael P | VP, Chief Accounting Officer | AWARD | 17,250 | — | — |
| Mar 1, 2026 | LEONARD JOHN M | President and CEO | AWARD | 156,400 | — | — |
| Mar 1, 2026 | LEONARD JOHN M | President and CEO | AWARD | 225,400 | — | — |
| Mar 1, 2026 | Lebwohl David | EVP, Chief Medical Officer | AWARD | 14,204 | — | — |
| Mar 1, 2026 | Schultes Birgit C | EVP, Chief Scientific Officer | AWARD | 39,200 | — | — |
| Mar 1, 2026 | BASTA JAMES | EVP, General Counsel | AWARD | 46,080 | — | — |
| Mar 1, 2026 | BASTA JAMES | EVP, General Counsel | AWARD | 65,829 | — | — |
| Mar 1, 2026 | Schultes Birgit C | EVP, Chief Scientific Officer | AWARD | 56,000 | — | — |
| Mar 1, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | AWARD | 61,280 | — | — |
| Mar 1, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | AWARD | 87,543 | — | — |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 3 neutral. Avg impact: 5.3/10.
NEUTRAL
PRESS-RELEASE
5/10
Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary
Jun 1, 2026
MIXED
8-K
6/10
Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3
May 11, 2026
BULLISH
8-K
8/10
Intellia Therapeutics announced positive Phase 3 topline data for its investigational CRISPR-based t
Apr 27, 2026
NEUTRAL
CLUSTER
3/10
Intellia Therapeutics insiders executed a mix of open-market sales and stock awards over the past we
Mar 3, 2026
NEUTRAL
INST-CLUSTER
4/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
MIXED
8-K
6/10
Intellia Therapeutics reported its Q4 and full-year 2025 financial results, highlighting a reduction
Feb 26, 2026
BEARISH
6/10
Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, wit
Apr 27, 2026
NEUTRAL
2/10
Intellia Therapeutics granted inducement RSUs covering 67,150 shares to 13 new employees outside its
Apr 3, 2026
NEUTRAL
3/10
Intellia Therapeutics granted inducement awards of 16,500 RSUs to six new employees outside its shar
Mar 6, 2026
BULLISH
8/10
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE t
Mar 2, 2026
Current analyst consensus: Hold (54% buy). Based on 28 analysts: 5 strong buy, 10 buy, 11 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$26.63 mean target
+119.9% upside
Strong Buy (2.09)
$8.00 Low
$95.00 High
| Metric | Value |
|---|---|
| Current Price | $12.11 |
| Target Low | $8.00 |
| Target Mean | $26.63 |
| Target Median | $19.00 |
| Target High | $95.00 |
| # Analysts | 19 |
| Recommendation | Strong Buy (2.09) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.80 | $-0.95 | $-0.63 | 18.9% | +9.7% | 10↑ 1↓ | $0.0B | -7.4% | 17 |
| Next Q 2026-09-30 |
$-0.79 | $-0.96 | $-0.64 | 14.2% | +11.3% | 10↑ 1↓ | $0.0B | -4.0% | 17 |
| Current FY 2026-12-31 |
$-3.17 | $-3.75 | $-2.76 | 16.8% | +4.3% | 12↑ 1↓ | $0.1B | -11.4% | 19 |
| Next FY 2027-12-31 |
$-1.80 | $-4.00 | $12.95 | 43.2% | +4.7% | 13↑ 1↓ | $0.3B | 343.4% | 19 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.795 | |
| 7d ago | $-0.798 | +0.002 |
| 30d ago | $-0.881 | +0.085 |
| 60d ago | $-0.899 | +0.104 |
| 90d ago | $-0.931 | +0.136 |
13 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| May 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 12, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 12, 2026 | Wedbush | REITERATE | Neutral | Neutral |
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Apr 28, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 28, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 27, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | Baird | MAINTAIN | Neutral | Neutral |
| Mar 4, 2026 | Jones Trading | UPGRADE | Hold | Buy |
| Mar 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Mar 3, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 3, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 10 | 11 | 2 | 0 | 54% | |
| May 1, 2026 | 6 | 11 | 11 | 2 | 0 | 57% | |
| Apr 1, 2026 | 6 | 11 | 11 | 2 | 0 | 57% | |
| Mar 1, 2026 | 5 | 10 | 13 | 2 | 0 | 50% | |
| Feb 1, 2026 | 5 | 10 | 13 | 2 | 0 | 50% | |
| Jan 1, 2026 | 6 | 11 | 12 | 2 | 0 | 55% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
5 mentions
0 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
Back to picks?
▲ 1
💬 1
⚡ 0.5
Jun 12, 2026
short_volume
Short Volume: NTLA — 60.8% short (1.5M / 2.5M)
Short: 1,494,364 | Exempt: 10,902 | TRF Vol: 2,457,514 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: NTLA — 67.8% short (1.9M / 2.8M)
Short: 1,876,291 | Exempt: 7,916 | TRF Vol: 2,768,129 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: NTLA — 61.9% short (1.0M / 1.6M)
Short: 973,083 | Exempt: 2,366 | TRF Vol: 1,572,041 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
contract
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=r5dtla-_3U7oeHeko3N3rSoW25mC12pJT7gQDe5OM
Jun 3, 2026
short_volume
Short Volume: NTLA — 65.0% short (0.9M / 1.4M)
Short: 882,177 | Exempt: 613 | TRF Vol: 1,357,868 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: NTLA — 59.5% short (1.2M / 2.0M)
Short: 1,195,568 | Exempt: 3,889 | TRF Vol: 2,009,963 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
earnings
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
<p>CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=snhSvrKq5vHJ-N_NqPDE1K1eFCUnrRo-gpPMYAZEY
May 18, 2026
short_volume
Short Volume: NTLA — 60.0% short (2.0M / 3.4M)
Short: 2,042,387 | Exempt: 49,721 | TRF Vol: 3,404,315 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: NTLA — 72.3% short (3.0M / 4.2M)
Short: 3,043,107 | Exempt: 3,063 | TRF Vol: 4,207,517 | Short Ratio: 72.3% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
<p>CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=nTzh8DyAxm4Wgi4gqstlsUjzJ5C8vFWK5CbHI493JR
May 5, 2026
other
Intellia Therapeutics to Participate in Upcoming Investor Conferences
<p align="left">CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dYoWTDw2hT7CpWMGhSzPrCOiDEGr5
May 5, 2026
short_interest
FTD: NTLA — 58,300 shares ($0.8M) failed to deliver
Settlement: 20260505, Price: $13.87, FTD Value: $808,621, INTELLIA THERAPEUTICS INC COM
Apr 30, 2026
earnings_calendar
NTLA Q1 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_interest
FTD: NTLA — 190,818 shares ($2.4M) failed to deliver
Settlement: 20260430, Price: $12.45, FTD Value: $2,375,684.1, INTELLIA THERAPEUTICS INC COM
Apr 29, 2026
offering
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
<p>CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=49FF8sgrBkurCLYP0VxixaFBCeeHdQD6NIY27hjd